
Releases
J&J Trial Shows Bispecific Combination Boosts Myeloma Survival
New Phase 3 data from the MonumenTAL-3 study demonstrates that combining TALVEY with DARZALEX FASPRO reduces the risk of disease progression or death by up to 72% in patients with relapsed or refractory multiple myeloma, marking a significant shift toward earlier-line use of bispecific immunotherapies.





















